drugset / Trial / NCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Phase 3
Recruiting
1273 enrolled
SWOG Cancer Research Network
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Timeline
- Start
- 2018-09-24
- Primary completion
- 2033-04-01
- Completion
- 2036-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Abiraterone acetate | Small molecule | — | Oral |
| Background | Bicalutamide | Other / unclassified | — | Oral |
| Background | Degarelix | Other / unclassified | — | Other |
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Background | Flutamide | Small molecule | — | Oral |
| Background | Goserelin | Other / unclassified | — | Subcutaneous |
| Background | Histrelin | Other / unclassified | — | Subcutaneous |
| Background | Leuprolide | Other / unclassified | — | Subcutaneous |
| Background | Nilutamide | Small molecule | — | Oral |
| Comparator | Prednisone | Other / unclassified | — | Oral |
| Background | Triptorelin | Other / unclassified | — | Other |